• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 12:39:52 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVEO alert in real time by email
    SC 13G/A 1 e620286_sc13ga-aveo.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 1) *

     

    AVEO Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    053588307

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐  Rule 13d-1(b)

     

    ☒  Rule 13d-1(c)

     

    ☐  Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

    ----------

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 053588307 13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     

     

    CUSIP No. 053588307 13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     

     

    CUSIP No. 053588307 13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

     

    CUSIP No. 053588307 13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

     

    CUSIP No. 053588307 13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    AVEO Pharmaceuticals, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    30 Winter Street

    Boston, Massachusetts 02108

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    053588307

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    CUSIP No. 053588307 13G Page 7 of 9

     

         
    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. - 0 shares

    Deerfield Management Company, L.P. - 0 shares

    Deerfield Partners, L.P. - 0 shares

    James E. Flynn – 0 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 0%

    Deerfield Management Company, L.P. - 0%

    Deerfield Partners, L.P. – 0%

    James E. Flynn – 0%

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 0

    Deerfield Management Company, L.P. - 0

    Deerfield Partners, L.P. - 0

    James E. Flynn – 0

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 0

    Deerfield Management Company, L.P. - 0

    Deerfield Partners, L.P. - 0

    James E. Flynn – 0

      

    **See footnotes on cover pages which are incorporated by reference herein.

     

    CUSIP No. 053588307 13G Page 8 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☒.

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

    CUSIP No. 053588307 13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: February 12, 2021

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of AVEO Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

    Get the next $AVEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVEO

    DatePrice TargetRatingAnalyst
    11/8/2022$15.00Buy → Hold
    Stifel
    7/12/2021$27.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVEO
    Financials

    Live finance-specific insights

    See more
    • AVEO Oncology Reports Third Quarter 2022 Financial Results

      – Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights At September 30, 2022, AVEO r

      11/7/22 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

      Acquisition Provides LG Chem's Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem's Efforts to Deliver Continued Growth AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of Patients with CancerAVEO to Establish and Operate as the U.S. Commercial Foundation for LG Chem Life Sciences' Oncology SegmentTransaction Price Represents a 43% Premium to AVEO's Closing Price on October 17, 2022 SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) and AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercia

      10/18/22 4:30:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Reports Second Quarter 2022 Financial Results

      – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call today at 4:30 p.m. ET – BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better

      8/4/22 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

      Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

      3/29/21 5:44:34 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FOTIVDA

      Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

      3/10/21 2:49:22 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    SEC Filings

    See more
    • SEC Form 15-12G filed by AVEO Pharmaceuticals Inc.

      15-12G - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/30/23 4:07:52 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.

      EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/24/23 12:15:15 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.

      EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/24/23 12:15:19 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bate Kenneth returned $5,625 worth of shares to the company (375 units at $15.00), decreasing direct ownership by 50% to 375 units (tax liability)

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:19:11 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Evnin Anthony B returned $627,615 worth of shares to the company (41,841 units at $15.00), closing all direct ownership in the company to satisfy tax liability

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:16:18 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ledell Jebediah (tax withholding)

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:16:10 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

      The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors. The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI. Keynote speakers include: Steve Kraus, Partner at Bessemer Venture Partners and world-renown

      3/22/24 6:14:00 PM ET
      $BEAM
      $DASH
      $LYFT
      $AVEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Consumer Discretionary
    • LG Chem Completes Acquisition of AVEO Oncology

      SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a fully diluted basis. "We are excited to complete LG Chem's acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world's leading oncology companies with a robust clinical pipeline of innovative therapies," said Shin Hak-Cheol, Chief Execu

      1/19/23 4:35:03 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Stockholders Approve Acquisition by LG Chem

      BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction. "Today's approval is a significant step toward the c

      1/5/23 7:35:35 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13D/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      11/1/22 5:01:48 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      10/20/22 4:05:20 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      2/11/22 3:32:10 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Leadership Updates

    Live Leadership Updates

    See more
    • AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

      - Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience - AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company's organizational efficiency and advancing its pipeline of products. "We are excited to welcome Jeb to the team during an important phase of AVEO's evolution as an integrated clinical development and commercial organization," said Michael Bailey, president and chief executive officer of AVEO. "With a successful

      12/1/21 7:00:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors

      AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company's Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. "Dr. Cullen, among the leading voices in cancer research and treatment, has made many important contributions to the evolving tre

      4/16/21 7:00:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update

      BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration’s (FDA) recent approval of FOTIVDA marks a transformative event for AVEO, and we are eager to demonstrate FOTIVDA’s potential to serve as a meaningful new treatment option within the growing relapsed or refractory advanced renal cell carcinoma (RCC) patient population. We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month,” said Michael Bailey, president and chief executive officer of AVEO. “In parallel, we remain focused on the evalua

      3/16/21 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVEO Oncology downgraded by Stifel with a new price target

      Stifel downgraded AVEO Oncology from Buy to Hold and set a new price target of $15.00

      11/8/22 6:15:04 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on AVEO Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of AVEO Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $27.00 previously

      7/12/21 6:05:44 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on AVEO Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of AVEO Pharmaceuticals with a rating of Outperform and set a new price target of $18.00 from $10.00 previously

      3/11/21 6:30:25 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care